Vanguard Capital Management
INMB icon

Vanguard Capital Management’s INmune Bio INMB Stock Holding History

Vanguard Capital Management’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.38M Hold
706,424
– – ﹤0.01% 3481
2026
Q2 		$1.15M Buy
706,424
+19,409
+3% +$26.9K ﹤0.01% 3566
2026
Q1 		$776K Buy
+687,015
New +$979K ﹤0.01% 3599

Other funds holding INMB

Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Westside Investment Management
Westside Investment Management Santa Monica, California $785M AUM 29.89% 1-Year Est. Return

Vanguard Capital Management's INMB Position: Q3 2026 in Review

Vanguard Capital Management held its INmune Bio (INMB) position steady in Q3 2026 at 706,424 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #3481.

Vanguard Capital Management first reported a position in INMB in Q1 2026 and has held it in 3 quarters since. 46 funds tracked by Wall St. Rank hold INMB as of Q3 2026.

  • Vanguard Capital Management held 706,424 shares of INmune Bio worth $1.38M as of Q3 2026.
  • Vanguard Capital Management left its INmune Bio share count unchanged in Q3 2026.
  • INmune Bio made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3481 holding.
  • Vanguard Capital Management first reported a position in INmune Bio in Q1 2026 and has held it in 3 quarters since.
  • 46 funds tracked by Wall St. Rank held INmune Bio as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.